Verrica Pharmaceuticals (VRCA) announced that it is growing its distribution network by entering into an agreement with Walgreens (WBA) to distribute YCANTH through its specialty pharmacy. Walgreens joins Verrica’s existing specialty pharmacy, Nufactor, who continues to be instrumental in helping the Company build awareness of YCANTH therapy among high volume dermatology and pediatric medical practices. “We are excited to enter into this agreement with Walgreens to help bring the first FDA-approved therapy for the treatment of molluscum contagiosum, YCANTH, to the millions of adults and children who contract this viral skin disease each year,” said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals. “Walgreens and Verrica mutually recognize the need to address this significant unmet medical need in dermatology, and we look forward to working together to provide greater access to YCANTH for patients in need. We will also continue to work closely with Nufactor, our other Specialty Pharmacy, who continues to be an extraordinary partner.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRCA:
- Insider Trading: Verrica Stock (NASDAQ:VRCA) Gained on $6.9M Insider Buy
- Biotech Alert: Searches spiking for these stocks today
- Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
- Torii Pharmaceutical reports ‘positive’ results from Phase 3 trial of TO-208
- Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results